Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Kyverna Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Kyverna Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$161.99M. For fiscal 2025 it was -$168.03M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$168.03M | – |
| FY2024 | Dec 31, 2024 | -$140.47M | – |
| FY2023 | Dec 31, 2023 | -$60.70M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$42.80M | – |
| Q2 FY2026 | Jun 30, 2026 | -$39.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.91M | – |
| Q3 FY2025 | Sep 30, 2025 | -$38.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.11M | – |
| Q1 FY2025 | Mar 31, 2025 | -$46.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$40.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$38.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.05M | – |
See a number that looks wrong?